Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
- VLP Therapeutics Eyes Japan Filing of Next-Gen mRNA Vaccine in Mid-2024: CEO
October 31, 2023
- BIKEN Files Updated Version of Measles-Rubella Vaccine Mearubik
October 31, 2023
- Hyftor Now Available in EU, UK: Nobelpharma
October 31, 2023
- Nippon Kayaku Gets Japan Commercial Rights to Anheart’s ROS1 Inhibitor
October 31, 2023
- Otsuka’s ADHD Med Hits Mark in PIII Pediatric Trials in US
October 30, 2023
- Sumitomo Awards AlphaNavi Worldwide Rights to Neuropathic Pain Therapy
October 27, 2023
- Takeda’s H1 Profit Tumbles on Write-Down Tied to Trial Setbacks, Outlook Slashed
October 27, 2023
- Merck Sues Sawai over Januvia Generics Approved in Japan
October 27, 2023
- Novartis Expects Limited Impact of siRNA Therapy in Drug Cost: Exec
October 26, 2023
- Yoshindo Recalls Some Nizatidine Products over Carcinogen Risks
October 26, 2023
- Japan Approves Spikevax for Primary Shots in Six Months and Above
October 26, 2023
- BMS Files Repotrectinib in Japan for ROS1-Positive NSCLC
October 26, 2023
- With Wholesalers Narrowed Down, Hospitals Face Squeezed Discounts for GSK Products
October 25, 2023
- Yakult to Divest Cancer Portfolio to Takata, Pull Plug on New Development
October 25, 2023
- Roche Group, Biogen Reach Settlement over Actemra Biosimilar
October 25, 2023
- Tecentriq Plus Avastin, Chemo Hit Goal in Extensive-Stage SCLC
October 25, 2023
- Ono, Turbine Ink Research Collab in Hunt for Oncology Targets
October 25, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…